PLSH · Panacea Life Sciences Holdings, Inc. · Executive Compensation
$0.08
At close · Nov 10
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 6, 2024
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.”View the 10-Q filed May 6, 2024
Market Cap
$1.46M
Shares
17.65M
Volume · Nov 10
1123
Avg daily vol (3M)
6856
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Janice Nerger | member of the Board of Directors | Resigned | 2022-07-22 |
Leadership
- Lawrence Wert CEO, Board Member
- Leslie Buttorff CEO, CFO, Board Member
- Larry Wert Chairman
- Alvaro Daniel Alberttis COO, Board Member
- Andrew Johnson Chief Accounting Officer
- Derek Du Chesne Board Member
- Emiliano Aloi Board Member
- Justin Viles Board Member
- Lawrence J. Wert Board Member